Visual Abstract

The prognostic role of microvascular complications (MVC) for all-cause death in patients with diabetes hospitalized for COVID-19 has been suggested. However, no detailed analysis of the microvascular burden is available so far. The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalized for COVID-19. The patients were enrolled after hospital admission from 03/10/2020 to 04/10/2020. MVC were defined as severe diabetic retinopathy (DR) and/or diabetic kidney disease (DKD, eGFR<60ml/min/1.73m2 and/or ACR>300mg/g) and/or diabetic foot ulcer (DFU). We analysed the association of MVC with death within 28 days after admission. The status for all 3 MVC was ascertained for 1755 participants including 1048 (60%) free of MVC. Patients with MVC were older, had lower BMI, HbA1c, AST/ALT concentration, lymphocyte and platelet counts, while sex, type of diabetes and CRP were not significantly different. Patients with any MVC had a sex- and age-adjusted OR for death of 2.54 (95%CI: 1.94-3.31, P<0.0001) compared to those without MVC. Figure details ORs for the different combinations of MVC. In patients with diabetes hospitalised for COVID-19, the microvascular burden associated with death within 28 days is dominated by DKD and DFU.


P. Saulnier: None. S. Hadjadj: Advisory Panel; Self; Valbiotis, Consultant; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi. L. Kessler: None. M. Marre: Board Member; Self; Merck Sharp & Dohme Corp., Consultant; Self; Novo Nordisk. J. Halimi: None. M. Wargny: None. P. Gourdy: Advisory Panel; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Mundipharma International, Novo Nordisk, Sanofi, Research Support; Self; Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company, Sanofi. B. Cariou: Board Member; Self; Bristol-Myers Squibb Company, Gilead Sciences, Inc., Lexicon Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Sanofi, Research Support; Self; Amgen Inc., AstraZeneca, Regeneron Pharmaceuticals Inc., Speaker’s Bureau; Self; Abbott Diabetes, Akcea Therapeutics. For the coronado study group: n/a.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at